Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
HilleVax, Inc. Market Cap
The HilleVax, Inc. (HLVX) share price is expected to increase by 55.44% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered HLVX. Price targets range from $2 at the low end to $5 at the high end. The current analyst consensus for HLVX is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assignedHLVX 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect HilleVax, Inc. to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on HLVX. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of HLVX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Matthew Caufield HC Wainwright & Co. | Neutral | $2 | Reiterates | Aug 12, 2024 |
| Stephen Willey Stifel | Hold | $3 | Downgrade | Jul 9, 2024 |
| David Risinger Leerink Partners | Market Perform | $2 | Downgrade | Jul 9, 2024 |
| Matthew Caufield HC Wainwright & Co. | Neutral | Downgrade | Jul 9, 2024 | |
| Seamus Fernandez Guggenheim | Neutral | Downgrade | Jul 8, 2024 | |
| Eric Joseph JP Morgan | Neutral | Downgrade | Jul 8, 2024 | |
| Eric Joseph JP Morgan | Overweight | $24 | Maintains | May 15, 2024 |
| Matthew Caufield HC Wainwright & Co. | Buy | $28 | Reiterates | May 10, 2024 |
| Matthew Caufield HC Wainwright & Co. | Buy | $28 | Reiterates | Mar 21, 2024 |
| Matthew Caufield HC Wainwright & Co. | Buy | $28 | Initiates | Dec 13, 2023 |
| Seamus Fernandez Guggenheim | Buy | $34 | Maintains | Nov 15, 2023 |
| Stephen Willey Stifel | Buy | $30 | Maintains | Nov 10, 2023 |
| Eric Joseph JP Morgan | Overweight | $22 | Maintains | May 16, 2023 |
| Eric Joseph JP Morgan | Overweight | $24 | Initiates | May 24, 2022 |
| Stephen Willey Stifel | Buy | $34 | Initiates | May 24, 2022 |
| Seamus Fernandez Guggenheim | Buy | $40 | Initiates | May 24, 2022 |
| David Risinger SVB Leerink | Outperform | $30 | Initiates | May 24, 2022 |
Morgan Stanley | Overweight | Upgrade | Mar 2, 2021 |
When did it IPO
2022
Staff Count
90
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Robert M. Hershberg M.D., Ph.D.
Market Cap
$98.6M
In 2023, HLVX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that HLVX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 14 Oct 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - HilleVax (HLVX) is upgraded to Zacks Rank #2 (Buy), indicating improved earnings prospects, which may positively impact the stock price in the near term.
Why It Matters - HilleVax's upgrade to Zacks Rank #2 indicates positive earnings outlook, potentially boosting investor sentiment and driving the stock price higher.
Wed, 28 Aug 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Levi & Korsinsky is investigating HilleVax, Inc. (NASDAQ: HLVX) for potential violations of federal securities laws, following a July 8, 2024 article by Fierce Biotech.
Why It Matters - The investigation into HilleVax may indicate potential legal issues or financial irregularities, impacting stock performance and investor sentiment.
Thu, 29 Aug 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Levi & Korsinsky is investigating HilleVax, Inc. (NASDAQ:HLVX) for potential federal securities law violations, following a July 8, 2024, article by Fierce Biotech.
Why It Matters - The investigation into HilleVax for potential securities law violations may signal underlying issues, potentially affecting stock performance and investor confidence.
Mon, 26 Aug 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Levi & Korsinsky is investigating HilleVax, Inc. (NASDAQ:HLVX) for potential violations of federal securities laws following a July 8, 2024, article by Fierce Biotech.
Why It Matters - HilleVax is under investigation for potential securities law violations, which could impact its stock price and investor confidence, affecting trading strategies and portfolio valuations.
Tue, 27 Aug 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Levi & Korsinsky has initiated an investigation into HilleVax, Inc. (NASDAQ: HLVX) for potential federal securities law violations, following a July 8, 2024 article by Fierce Biotech.
Why It Matters - The investigation into HilleVax for potential securities law violations could signal financial instability or fraud, impacting investor confidence and stock performance.
Fri, 23 Aug 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Levi & Korsinsky has initiated an investigation into HilleVax, Inc. (NASDAQ: HLVX) for potential federal securities law violations, following a July 8, 2024 article by Fierce Biotech.
Why It Matters - The investigation into HilleVax for potential securities law violations could impact its stock price and investor confidence, leading to volatility or legal repercussions for shareholders.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
